EP1054012A4 - Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen - Google Patents

Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen

Info

Publication number: EP1054012A4
Authority: EP; European Patent Office
Prior art keywords: receptor antagonists; preventives; remedies; adenosine; diabetes
Prior art date: 1998-01-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP98961528A

Other languages

English (en)

French (fr)

Other versions

EP1054012A1 (de

EP1054012B1 (de

Inventor

Osamu Asano

Hitoshi Harada

Yorihisa Hoshino

Seiji Yoshikawa

Takashi Inoue

Tatsuo Horizoe

Nobuyuki Yasuda

Kaya Nagata

Junsaku Nagaoka

Manabu Murakami

Seiichi Kobayashi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai Co Ltd

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-05

Filing date

1998-12-24

Publication date

2001-12-12

1998-12-24 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1998-12-24 Priority to EP02029118A priority Critical patent/EP1300147A1/de

2000-11-22 Publication of EP1054012A1 publication Critical patent/EP1054012A1/de

2001-12-12 Publication of EP1054012A4 publication Critical patent/EP1054012A4/de

2003-06-11 Application granted granted Critical

2003-06-11 Publication of EP1054012B1 publication Critical patent/EP1054012B1/de

2018-12-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

EP98961528A 1998-01-05 1998-12-24 Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen Expired - Lifetime EP1054012B1 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP02029118A EP1300147A1 (de)	1998-01-05	1998-12-24	Purinderivate und Adenosin-A2 Rezeptorantagonist als vorbeugendes oder therapeutisches Mittel für Zuckerkrankheitsmellitus

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP52698		1998-01-05
JP52698		1998-01-05
PCT/JP1998/005870 WO1999035147A1 (fr)	1998-01-05	1998-12-24	Derives de purine et antagonistes du recepteur a2 d'adenosine utiles comme moyens de prevention/traitement du diabete

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP02029118A Division EP1300147A1 (de)	1998-01-05	1998-12-24	Purinderivate und Adenosin-A2 Rezeptorantagonist als vorbeugendes oder therapeutisches Mittel für Zuckerkrankheitsmellitus

Publications (3)

Publication Number	Publication Date
EP1054012A1 EP1054012A1 (de)	2000-11-22
EP1054012A4 true EP1054012A4 (de)	2001-12-12
EP1054012B1 EP1054012B1 (de)	2003-06-11

Family

ID=11476226

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP98961528A Expired - Lifetime EP1054012B1 (de)	1998-01-05	1998-12-24	Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen
EP02029118A Withdrawn EP1300147A1 (de)	1998-01-05	1998-12-24	Purinderivate und Adenosin-A2 Rezeptorantagonist als vorbeugendes oder therapeutisches Mittel für Zuckerkrankheitsmellitus

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP02029118A Withdrawn EP1300147A1 (de)	1998-01-05	1998-12-24	Purinderivate und Adenosin-A2 Rezeptorantagonist als vorbeugendes oder therapeutisches Mittel für Zuckerkrankheitsmellitus

Country Status (7)

Country	Link
US (2)	US6579868B1 (de)
EP (2)	EP1054012B1 (de)
AT (1)	ATE242775T1 (de)
AU (1)	AU1688599A (de)
CA (1)	CA2315736A1 (de)
DE (1)	DE69815554T2 (de)
WO (1)	WO1999035147A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ27399A3 (cs) *	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
DE19917785A1 (de) *	1999-04-20	2000-10-26	Bayer Ag	2,4-Diamino-pyrimidin-Derivate
GB9915437D0 (en)	1999-07-01	1999-09-01	Cerebrus Ltd	Chemical compounds III
KR100694684B1 (ko)	1999-07-02	2007-03-13	에자이 알앤드디 매니지먼트 가부시키가이샤	축합 이미다졸 화합물 및 당뇨병 치료약
US7189717B2 (en) *	2000-04-26	2007-03-13	Eisai Co., Ltd.	Medicinal compositions promoting bowel movement
GB0100624D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VII
GB0100623D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds IV
GB0100620D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical cokpounds V
NZ528216A (en) *	2001-02-24	2006-12-22	Boehringer Ingelheim Pharma	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
JPWO2002079204A1 (ja) *	2001-03-28	2004-07-22	協和醗酵工業株式会社	８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
JP5280597B2 (ja)	2001-03-30	2013-09-04	サンスター技研株式会社	一液加熱硬化型エポキシ樹脂組成物および半導体実装用アンダーフィル材
EP1404675B1 (de) *	2001-07-03	2008-03-12	Novo Nordisk A/S	Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
US6869947B2 (en)	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ITRM20010465A1 (it)	2001-07-31	2003-01-31	Sigma Tau Ind Farmaceuti	Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
JP4514452B2 (ja) *	2001-10-01	2010-07-28	ユニバーシティオブバージニアパテントファウンデーション	Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
TWI301834B (en) *	2001-10-22	2008-10-11	Eisai R&D Man Co Ltd	Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (de) *	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
EP2942082B1 (de)	2002-01-28	2019-03-06	Kyowa Hakko Kogyo Co., Ltd	A2a rezeptor antagonisten zur verwendung in der behandlung von bewegungsstörungen
EP1338595B1 (de) *	2002-02-25	2006-05-03	Eisai Co., Ltd.	Xanthin-Derivate als DPP-IV-Inhibitoren
JP2004018453A (ja) *	2002-06-14	2004-01-22	Sumika Fine Chemicals Co Ltd	アルキニルプリン化合物およびその製造方法
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) *	2002-08-22	2009-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en)	2002-08-22	2009-08-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10238477A1 (de) *	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7129239B2 (en) *	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US7482337B2 (en)	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) *	2002-11-21	2004-06-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
WO2004092170A2 (en)	2003-04-09	2004-10-28	Biogen Idec Ma Inc.	Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
EP1615931A1 (de)	2003-04-09	2006-01-18	Biogen Idec MA Inc.	Triazolopyrazine und verfahren zu deren herstellung und anwendung
US7834014B2 (en)	2003-04-09	2010-11-16	Biogen Idec Ma Inc.	A2a adenosine receptor antagonists
US7566707B2 (en)	2003-06-18	2009-07-28	Boehringer Ingelheim International Gmbh	Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de)	2003-11-27	2005-06-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7256196B1 (en) *	2003-12-09	2007-08-14	The Procter & Gamble Company	Purine cytokine inhibitors
ES2532479T3 (es)	2004-01-28	2015-03-27	Kyowa Hakko Kirin Co., Ltd.	Agentes para el tratamiento de la migraña
US7501426B2 (en) *	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de)	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en)	2004-03-13	2008-07-01	Boehringer Ingleheim International Gmbh	Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
CN1972945A (zh) *	2004-04-02	2007-05-30	腺苷治疗有限责任公司	A2a腺苷受体的选择性拮抗剂
US7179809B2 (en) *	2004-04-10	2007-02-20	Boehringer Ingelheim International Gmbh	2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en)	2004-05-10	2008-10-21	Boehringer Ingelheim International Gmbh	Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de)	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de)	2004-09-11	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) *	2004-09-14	2006-03-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) *	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US8003331B2 (en) *	2005-08-12	2011-08-23	Astellas Pharma Inc.	Method for identifying target protein of drug and method for screening therapeutic agent for diabetes using the target protein
AU2006287521A1 (en) *	2005-09-07	2007-03-15	Plexxikon, Inc.	PPARactive compounds
ES2273599B1 (es)	2005-10-14	2008-06-01	Universidad De Barcelona	Compuestos para el tratamiento de la fibrilacion auricular.
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EA030606B1 (ru)	2006-05-04	2018-08-31	Бёрингер Ингельхайм Интернациональ Гмбх	Способы приготовления лекарственного средства, содержащего полиморфы
EP2057160A1 (de)	2006-08-08	2009-05-13	Boehringer Ingelheim International GmbH	Pyrrolo[3,2-d]pyrimidine als dpp-iv-inhibitoren zur behandlung von diabetes mellitus
EA200970746A1 (ru) *	2007-02-09	2010-02-26	Такеда Фармасьютикал Компани Лимитед	Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма
US20090068236A1 (en) *	2007-04-13	2009-03-12	Chemgenex Pharmaceuticals, Inc.	Oral Cephalotaxine Dosage Forms
KR101610005B1 (ko) *	2007-08-17	2016-04-08	베링거 인겔하임 인터내셔날 게엠베하	Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
GB0906579D0 (en)	2009-04-16	2009-05-20	Vernalis R&D Ltd	Pharmaceuticals, compositions and methods of making and using the same
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
EA031225B1 (ru) *	2008-08-15	2018-12-28	Бёрингер Ингельхайм Интернациональ Гмбх	Ингибиторы дпп-4 для заживления ран
EP2344195A2 (de)	2008-09-10	2011-07-20	Boehringer Ingelheim International GmbH	Kombinationstherapie zur behandlung von diabetes und zugehörigen leiden
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt)	2008-12-23	2015-08-11	Boehringer Ingelheim Int	Formas salinas de compostos orgânico
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
DK2408775T3 (en)	2009-03-20	2015-07-27	Sigma Tau Ind Farmaceuti	Oxidized derivatives of triazolylpuriner useful as ligands of the adenosine A 2A receptor, and their use as medicaments
ES2760917T3 (es)	2009-11-27	2020-05-18	Boehringer Ingelheim Int	Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
US20130109645A1 (en)	2010-03-31	2013-05-02	The united States of America,as represented by Secretary,Dept.,of Health and Human Services	Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
ES2365960B1 (es)	2010-03-31	2012-06-04	Palobiofarma, S.L	Nuevos antagonistas de los receptores de adenosina.
JP6034781B2 (ja)	2010-05-05	2016-11-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	併用療法
EA201991014A1 (ru)	2010-06-24	2019-09-30	Бёрингер Ингельхайм Интернациональ Гмбх	Лечение диабета
AU2011303420B2 (en) *	2010-09-13	2014-03-20	Impetis Biosciences Ltd.	Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
MX366629B (es)	2011-07-15	2019-07-17	Boehringer Ingelheim Int	Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
ES2795418T3 (es)	2012-02-17	2020-11-23	Res Triangle Inst	Derivados de difenil purina restringidos periféricamente
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP3685839A1 (de)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
KR102339228B1 (ko)	2013-08-23	2021-12-13	뉴파마, 인크.	특정 화학 물질, 조성물, 및 방법
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
US10947201B2 (en)	2015-02-17	2021-03-16	Neupharma, Inc.	Certain chemical entities, compositions, and methods
WO2017188287A1 (ja) *	2016-04-26	2017-11-02	大日本住友製薬株式会社	置換プリン誘導体
JP2019517542A (ja)	2016-06-10	2019-06-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	リナグリプチンおよびメトホルミンの組合せ
CN109843858B (zh) *	2016-08-15	2023-05-05	润新生物公司	某些化学实体、组合物及方法
HRP20230251T1 (hr)	2017-08-01	2023-04-14	Merck Patent Gmbh	Derivati tiazolopridina kao antagonisti adenozinskih receptora
BR112020003594A2 (pt)	2017-08-21	2020-09-01	Merck Patent Gmbh	derivados de benzimidazol como antagonistas de receptor de adenosina
WO2019038214A1 (en)	2017-08-21	2019-02-28	Merck Patent Gmbh	QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
JP2022505872A (ja)	2018-10-25	2022-01-14	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	アデノシン受容体アンタゴニストとしての５－アザインダゾール誘導体
AU2019363662A1 (en)	2018-10-25	2021-03-25	Merck Patent Gmbh	5-azaindazole derivatives as adenosine receptor antagonists
AR117844A1 (es)	2019-01-22	2021-09-01	Merck Patent Gmbh	Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69130869T2 (de) *	1990-10-18	1999-06-10	Kyowa Hakko Kogyo Kk	Xanthinderivate
US5256398A (en) *	1990-11-08	1993-10-26	Whitby Research, Inc.	Composition for determining viability of tissue
GB9125002D0 (en) *	1991-11-25	1992-01-22	Ici Plc	Azole derivatives
DE19501482A1 (de) *	1995-01-19	1996-07-25	Bayer Ag	2,9-disubstituierte Purin-6-one
WO1997001551A1 (en)	1995-06-26	1997-01-16	Fujisawa Pharmaceutical Co., Ltd.	Pyrazole compounds and pharmaceutical compositions
DE19541264A1 (de) *	1995-11-06	1997-05-07	Bayer Ag	Purin-6-on-derivate
WO1997046560A1 (fr) *	1996-06-06	1997-12-11	Otsuka Pharmaceutical Factory, Inc.	Derives d'amides
US6511984B2 (en) *	2000-03-30	2003-01-28	Pfizer Inc.	Neuropeptide Y antagonists

1998
- 1998-12-24 AT AT98961528T patent/ATE242775T1/de not_active IP Right Cessation
- 1998-12-24 US US09/582,840 patent/US6579868B1/en not_active Ceased
- 1998-12-24 DE DE69815554T patent/DE69815554T2/de not_active Expired - Fee Related
- 1998-12-24 WO PCT/JP1998/005870 patent/WO1999035147A1/ja active IP Right Grant
- 1998-12-24 CA CA002315736A patent/CA2315736A1/en not_active Abandoned
- 1998-12-24 US US11/057,854 patent/USRE39112E1/en not_active Expired - Fee Related
- 1998-12-24 EP EP98961528A patent/EP1054012B1/de not_active Expired - Lifetime
- 1998-12-24 EP EP02029118A patent/EP1300147A1/de not_active Withdrawn
- 1998-12-24 AU AU16885/99A patent/AU1688599A/en not_active Abandoned

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number	Publication date
ATE242775T1 (de)	2003-06-15
DE69815554T2 (de)	2004-05-06
DE69815554D1 (de)	2003-07-17
EP1054012A1 (de)	2000-11-22
US6579868B1 (en)	2003-06-17
USRE39112E1 (en)	2006-05-30
AU1688599A (en)	1999-07-26
EP1300147A1 (de)	2003-04-09
EP1054012B1 (de)	2003-06-11
WO1999035147A1 (fr)	1999-07-15
CA2315736A1 (en)	1999-07-15

Legal Events

Date	Code	Title	Description
2000-10-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2000-11-22	17P	Request for examination filed	Effective date: 20000705
2000-11-22	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2001-12-12	A4	Supplementary search report drawn up and despatched	Effective date: 20011026
2001-12-12	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-06-19	17Q	First examination report despatched	Effective date: 20020508
2002-10-30	GRAH	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOS IGRA
2003-03-19	GRAH	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOS IGRA
2003-04-25	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2003-06-11	AK	Designated contracting states	Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2003-06-11	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030611 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030611 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20030611 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030611 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030611 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030611 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030611
2003-06-11	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2003-06-11	RIC1	Information provided on ipc code assigned before grant	Ipc: 7A 61K 31/52 B Ipc: 7C 07D 473/30 B Ipc: 7C 07D 473/00 A
2003-06-13	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2003-07-09	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2003-07-17	REF	Corresponds to:	Ref document number: 69815554 Country of ref document: DE Date of ref document: 20030717 Kind code of ref document: P
2003-09-11	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030911 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030911 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030911 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030911
2003-09-22	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030922
2003-11-03	NLV1	Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
2003-12-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2003-12-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031224 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031224 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031224
2003-12-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031231
2004-04-02	ET	Fr: translation filed
2004-04-16	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2004-04-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2004-06-02	26N	No opposition filed	Effective date: 20040312
2004-09-22	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2004-12-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20041217 Year of fee payment: 7
2004-12-21	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20041221 Year of fee payment: 7
2004-12-27	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20041227 Year of fee payment: 7
2005-12-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20051224
2006-07-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060701
2006-08-23	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20051224
2006-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060831
2006-11-17	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20060831

Publication	Publication Date	Title
EP1054012A4 (de)	2001-12-12	Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen
NZ522326A (en)	2006-03-31	Adenosine A2A receptor antagonists
BR0116607A (pt)	2004-04-20	Derivados de glicopiranosiloxipirazol e uso dos mesmos em medicamentos
AP2003002911A0 (en)	2003-12-31	An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
BR0207658A (pt)	2005-10-25	Métodos para o tratamento ou a prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, de obesidade, de diabetes melito, de disfunção sexual masculina ou feminina, e de disfunção erétil em um mamìfero que disto necessita, e, composição farmacêutica
IL186200A (en)	2013-09-30	Use of amylin and agonists, analogues and derivatives of amylin for the preparation of a drug for the treatment of psychiatric illness
WO2007002945A3 (en)	2007-03-29	P2y6 receptor agonists for treating lung diseases
NL970006I2 (nl)	1997-10-01	Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
ES2091689T3 (es)	1996-11-01	Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos.
BR0317436A (pt)	2005-11-16	Usos de antagonistas do receptor a2a de adenosina
WO2000064441A3 (en)	2001-06-14	Compound for use as a medicament for treatment of disorders involving bronchocontraction
EP1145717A3 (de)	2002-08-14	Synergistische Wirkung von einem Sulfonylharnstoff und/oder einem nicht Sulfonylharnstoff K-ATP Kanalblocker und einem cAMP-Phosphodiestrerase Typ 3 Inhibitor
UA97468C2 (ru)	2012-02-27	Комбинация и фармацевтическая композиция, которая содержит 8-[3-аминопиперидин-1-ил]ксантины, способ ее получения и их применение в качестве лекарственного средства
AR063148A1 (es)	2008-12-30	Composicion para tratar la dependencia a la nicotina que comprende al menos un antagonista del receptor nicotinico alfa 3 beta 4 y al menos un metabolito de l a nicotina y su uso para preparar un medicamento
WO1997020823A3 (en)	1997-07-17	2-amino quinazoline derivatives as npy receptor antagonists
EP1183245A4 (de)	2002-10-02	Selektive npy(y5)-antagonisten
WO2002044192A1 (fr)	2002-06-06	Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions
NO20072389L (no)	2007-08-23	Substituerte benzokinolizinderivater
TR200103409T2 (tr)	2002-05-21	Glukoz çıkışı arttırıcıları olarak naftalen üreleri.
HUP9800938A2 (hu)	1999-01-28	NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
BR9813169A (pt)	2000-08-22	Derivados de ciclopenteno úteis como antagonistas do receptor de motilina
GEP20094697B (en)	2009-06-10	Condensed purine derivatives as a1 adenosine receptor antagonists
NO996442L (no)	2000-02-28	Anvendelse av en spesifikk antagonist for 5HT2 reseptorer for fremstilling av medisiner som er anvendbare for behandling av søvnapnésyndromet
IL149486A0 (en)	2002-11-10	Purine derivatives and pharmaceutical compositions containing the same
IL206567A0 (en)	2011-07-31	Use of an agonist to the igs4 neuromdin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or activity of the igs4 neuromedin receptor ploypeptide